Proenzyme technology
搜索文档
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
Globenewswire· 2025-11-10 21:45
Initial Investment of $1 Million Received from Hexstone Capital LLC Upon ClosingMELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Trea ...
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline
Globenewswire· 2025-11-10 21:45
MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC ("Hexstone"), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, D ...